Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Using the NIH two-phase microlymphocytotoxic test, lymphocytes of patients and control subjects were typed for HLA antigens of A and B loci: A1, 2, 3, 9, 10, 11, 28 (or Aw 19, A30, 31), B5, 7, 8, 12, 13, 14, 15, 17, 18, 21, w22, 27, 35, 40. Patients tested: 1. 75 patients with Wilms' tumour, thereof 35 had their whole families tested, 2. 20 patients with neuroblastoma, 3. 26 patients with neurofibromatosis, thereof 21 had their whole families tested, 4. 166 patients with testicular germinal tumours and 41 children with germinal tumours of diverse localization, 5. 48 individuals with haemangioma, 6. 64 women with breast cancer and 50 with dysplasia. We investigated 490 patients and, with the addition of family studies, another 193 individuals, altogether 683 persons. The results were compared with a group of 301 healthy non-related persons or with a group of 116 healthy non-related men, or with 100 healthy women and, in the family studies, with members of 47 healthy three-member families with healthy children. The chi 2 test with a Yates correction or also Fisher's exact test were used for the purpose. The resultant p was corrected using multiplication by the number of the antigens typed. In some cases we used the relative risk (RR) value. The results can be summed up in the following seven points: 1. Wilms' tumour was found to have no significant association either in our population or family studies. The latter seem to testify rather against this tumour's linkage with HLA. Our study was inconclusive as to the significance of the more frequent incidence of HLA-A1 and/or A9 in the diseased children of those families where one of the parents had at least one of those antigens. It cannot be ruled out as a sign of better prognosis. We regards as indispensable the typing of HLA antigens in patients with Wilms' tumour coincident with an inborn anomaly, as well as in members of those patients' families, and also a conclusive elucidation of the possible association with HLA-A1 and/or A9. No other centre has as yet undertaken any family studies. Consequently our possibilities of comparison with other teams' results were meagre. 2. We point to the possible conceivable relationship between neuroblastoma and HLA-B13. We found this association, albeit non-significant after correction, potentially important, especially after comparisons with the results of an only other existing study.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:HLA system and some neoplastic diseases. 307 Nov 20

Immunohistochemical evaluation of 200 primary breast cancers with the anti-p53 mouse monoclonal antibody (MAb) PAb421 showed positivity in nuclei of malignant cells in 31 cases (15.5%). PAb421+ cases were significantly more frequently epidermal growth factor receptor (EGF-R)-positive (67.7%; p less than 0.001) and estrogen receptor (ER)-negative (73.3%; p less than 0.001); they displayed surface histocompatibility class-1 (80.6%; p less than 0.01) and 11 (74.2%; p less than 0.05) antigens. Low values for progesterone receptor (mean 67.20 +/- 25.2 fmol/mg; p less than 0.05) and a high number of cells positive for the proliferation-associated antigen Ki-67 (log mean 6.88 +/- 0.33; p less than 0.01) were found in PAb421+ tumors as well as a high number of grade-3 infiltrating duct carcinomas (70%; p = 0.01). Of the 200 cases of mammary carcinoma, 88 were further analyzed using another human specific anti-p53 MAb PAb1801, and 40 (45.5%) were found positive. This MAb stained all the PAb421+ cases and was significantly associated with negative ER status (39.5%; p less than 0.05) and high Ki-67 scores (log mean 6.93 +/- 0.24; p = 0.001). Analysis of PAb1801+/Pab421- cases for HLA antigens, EGF-R and ER showed a phenotype similar to that of the p53-ve/ER+ carcinomas, except for the high Ki-67 score. No differences in age of the patient, number of involved nodes, tumor size, ploidy or labelling index scores were evident between p53+ and carcinomas. We concluded that p53 in mammary carcinomas is associated with ER-negative, growth factor receptor-positive, high-grade tumors, and is a promising new parameter to evaluate the cellular biology and prognosis of breast cancer.
 ...
PMID:P53 expression in breast cancer. 327 32

The effects of intralesional injections of human natural and recombinant interferons-alpha (nIFN-alpha and rIFN-alpha A) were studied in nude mice bearing bilateral xenografts of human mammary carcinoma cells (BT 20, MCF-7). One tumor of each animal received intralesional injections, while the contralateral tumor was left undisturbed. Thus, the injected tumors were subjected to the local action of the IFNs whereas the opposite ones were exposed to the systemic effects of the IFNs seeping into the subcutaneous tissue following the intratumoral injection. When used singly these IFNs exerted an inhibitory effect on the growth of both injected and contralateral tumors, but failed to cause complete regression. Many of the cells of treated BT 20 xenografts showed significant morphological alterations (increased cell volume and nuclear pleomorphism) as compared to the untreated controls. Morphological alterations in MCF-7 tumors were difficult to assess because of the inherent pleomorphism of these cells. The immunoreactivity of BT 20 and MCF-7 tumors to monoclonal antibodies directed against milk fat globule proteins and against HLA antigens was not appreciably affected by treatment with these IFNs. This study confirms that intralesional injections of human IFNs-alpha partially inhibit the growth of human breast cancer xenografts, probably through a direct effect on the carcinoma cells. Under the present experimental conditions, the intralesional and the subcutaneous routes of administration appear to offer comparable antitumor effectiveness.
 ...
PMID:Effects of intralesional injections of interferons-alpha on xenografts of human mammary carcinoma cells (BT20 and MCF-7). 337 24

100 patients suffering from breast cancer and 112 healthy female blood donors from Bremen have been investigated for associations between HLA antigens and this disease. Altogether 58 different antigens of the HLA-A-, B- and -C-loci were typed. Some associations were found regarding Bw22 and Bw55, which, however, are statistically not significant.
 ...
PMID:[Association of major histocompatibility complex antigens (HLA antigens) and breast carcinoma]. 346 34

Clusters of plasmacytoid T cells (PTC) were detected in axillary lymph nodes draining an invasive ductal breast cancer in a 64-year-old woman. Immunocytology of PTC revealed a remarkable antigenic profile. Analysis with a broad spectrum of monoclonal antibodies demonstrated that PTC bear the CD4 surface antigen (Leu-3a+ and OKT4+), the transferrin receptor (OKT9+), and components of the HLA class-II antigens (TU35+, TU39+, Leu-10+). Surprisingly, PTC were stained by two monoclonal antibodies recognizing monocytes and macrophages (Ki-M6 and Ki-M7). Finally, Leu-8, which detects most mature T lymphocytes, also identified the PTC, and all pan T-cell markers (Leu-1, UCHT 1, and Lyt 3) were constantly negative. The cytogenesis and the functional properties of PTC remain a matter of discussion.
 ...
PMID:Immunocytology of plasmacytoid T cells: marker analysis indicates a unique phenotype of this enigmatic cell. 349 97

Effects of prolactin on Class II HLA Ag expression have been identified for the first time in a human breast cancer cell line maintained in long-term tissue culture (MCF7) and were reported in this work as follows. Quantification methods for assaying Class II HLA Ag expression modulated by prolactin were established. Class II HLA Ags were internally labelled with [35S] methionine, extracted with Nonidet P-40, immunoprecipitated specifically with anti-Class II HLA MoAbs, isolated on protein A-Sepharose and quantified by chromatofocusing. For low doses of prolactin added to a final concentration (0.015 to 0.350 micrograms/ml culture medium), no change in Class II HLA Ags expressed by MCF7 cells was observed, when compared with controls, the percent of Class II HLA Ags assayed by chromatofocusing was then 4.03 +/- 0.57. For high doses of prolactin added to the final concentration (1.50 micrograms to 3.00 micrograms/ml medium), the percent of Class II HLA Ags increased to 6.05 +/- 0.72. When prolactin was added to the culture medium of MCF7 human breast cancer cell line, increased Class II HLA Ag expression by membrane cells was noted. Prolactin induction of Class II HLA Ag expression by human breast cancer cell lines should prove very useful to study the biology of prolactin in the tumorogenesis of the human breast.
 ...
PMID:Effect of prolactin on class II HLA antigen expression by MCF7 cell line. 351 93

An analysis of the findings in 21 patients with the Cowden syndrome or the multiple hamartoma syndrome is presented. The Cowden syndrome is a cancer-associated genodermatosis with characteristic mucocutaneous findings and a wide array of associated abnormalities including a high incidence of breast cancer in female patients. Genetic studies confirmed autosomal dominant inheritance with a high penetrance in both sexes and moderate interfamilial and intrafamilial differences in the expressivity of a number of symptoms. Familial occurrence was present in 4 of the 7 families. There was a strong predominance of female patients (6:1), which may be fortuitous. Mucocutaneous changes were the most constant (100% incidence) and characteristic findings; they almost invariably became manifest in the second decade. Four of our 18 female patients (22%) were treated for breast cancer, a lower incidence than reported previously. No increased incidence of other types of malignancies was found. Craniomegaly (high head circumference) was found to be the most common extracutaneous manifestation (80% incidence); craniomegaly appears to be an important early marker. We also found high incidences of gastrointestinal polyps (approximately 60%) and cutaneous fibromas (76%), while the incidence of thyroid abnormalities, thus far regarded as the most common extracutaneous finding, was similar to that reported previously (62%). G-banded karyotype and preliminary DNA-repair studies revealed no clear abnormalities. No linkage with the loci of HLA, and immunoglobulin haplotypes was found.
 ...
PMID:The Cowden syndrome: a clinical and genetic study in 21 patients. 369 31

One case of the so-called "Stewart-Treves syndrome" (STS), appearing on a lymphoedematous arm complicating radical mastectomy for breast cancer, was characterized electronmicroscopically and immunohistologically, in order to elucidate its disputed (epithelial vs endothelial) histogenesis. Epithelial and endothelial differentiation markers used comprised: antibodies against keratin, vimentin, factor VIII-related antigen (F VIII-RA), HLA-DR antigens and the lectin Ulex europeaus agglutinin I (UEA I). At the ultrastructural level, neoplastic cells were found to contain typical Weibel-Palade bodies, whereas by immunohistological techniques they proved to be keratin-negative/vimentin+, F VIII-RA+, UEAI+, HLA-DR+. These results rule out a possible epithelial differentiation and strongly favour an endothelial one for STS.
 ...
PMID:Stewart-Treves syndrome: an histogenetic (ultrastructural and immunohistological) study. 370 Jul 72

A group of 157 women with primary breast cancer (BC) were typed for HLA antigens, and gene frequencies were compared to those of 327 control healthy individuals. Diagnosis of BC was made for all patients on surgical mastectomy specimens; histologic grading, estrogen (ER) and progesterone (PgR) receptors were determined on all primary tumors. Typed antigens included the majority of the specificities controlled by the HLA-A, -B and -C loci, according to the 8th International Histocompatibility Testing Workshop recommendations. No significant discrepancy in their frequencies was found in the undivided sample as compared to controls. The analysis of HLA gene frequency was extended to subsets of patients identified by the following prognostic features: (a) age at tumor diagnosis (pre-menopause vs. post-menopause); (b) receptor status (presence vs. absence of ER and PgR); (c) mammary gland dysplasia (presence vs. absence); (d) histologic grade (grade 3 vs. grades 1 and 2 combined); (e) time to relapse before or after 24 months following mastectomy). A moderate deviation from normal of some genes was found in several subsets, often affecting only one of the antithetical subgroups (feature present vs. feature absent). In the instance of B5, the increase in frequency of the gene in one of the subset pair (ER + subjects) was balanced by a decrease of the same gene in the counterpart (ER-subjects). Increased frequencies were found for the B7 gene in the following prognostic groups: (a) lack of ER (0.08); (b) lack of PgR (0.09); (c) absence of mammary dysplasia (0.075); (d) histologic grade 3 (0.10); and (e) premenopause (0.12), the last two showing significant divergence from normal. When features (d) and (e) on the one hand and (a), (b), (d) and (e) on the other were combined, B7 reached frequencies of 0.18 (p less than 5 X 10(-4] and of 0.29 (p less than 5 X 10(-6], respectively.
 ...
PMID:HLA and prognostic factors in primary breast cancer. 387 17

Effectiveness of recombinant DNA (rDNA) human interferon alpha 2 (IFN alpha 2) in advanced breast cancer was evaluated in 14 patients who had received prior endocrine and/or cytotoxic therapy. After randomization, 7 patients received IFN alpha 2 two million IU m-2 day-1, s.c., 3 times a week (schedule 1) and 7 patients received 50 million IU m-2 day-1, i.v., for 5 consecutive days, every 3 weeks (schedule 2). Treatment duration was 4-21 weeks in schedule 1 and 6-24 weeks (2-8 courses) in schedule 2. Regressions were not achieved with either schedule. Treatment was associated with significant toxicity and was more severe in schedule 2. Dose limiting toxicities were leukopenia, elevation of liver enzymes, hyperglycemia and fatigue. Serum IFN activity was low or undetectable in patients on schedule 1 and high in patients on schedule 2. At 24 h, serum IFN activity was detectable in only 1/6 patients on schedule 1 as compared to 3/7 patients on schedule 2. IFN neutralizing factors were detected in the serum of only 1 patient prior to treatment but none were detected in any of the patients during or after discontinuation of treatment (4-24 weeks). IFN alpha 2 increased the expression of both HLA class 1 antigens and beta 2 microglobulin in peripheral blood lymphocytes in vivo. This effect was dose related.
 ...
PMID:Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial. 391 78


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>